A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)

NCT02423122 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease
Mild Cognitive Impairment

Interventions

DRUG: VX-745

Sponsor

EIP Pharma Inc